Follicular lymphoma: watch and wait is watch and worry
Mené sur 379 patients atteints d'un lymphome folliculaire asymptomatique de grade 1, 2 ou 3a, cet essai international de phase III évalue l'intérêt du rituximab en traitement d'entretien pour retarder le besoin d'une chimiothérapie ou d'une radiothérapie et améliorer la qualité de vie
The selection of initial treatment for patients with follicular non-Hodgkin lymphoma is not a straightforward decision. Physicians who treat patients with follicular lymphoma will usually have a long conversation with a newly diagnosed patient who has a low burden of disease to decide whether a watch and wait approach is best for the patient, compared with treatment with either monoclonal antibodies or combination chemoimmunotherapy. Patients often have many questions and the decision to watch ...
The Lancet Oncology , commentaire, 2013